About Pleuropulmonary Blastoma
Pleuropulmonary blastoma is the most common primary malignant lung tumour in childhood and is strongly associated with germline or somatic mutations in the DICER1 gene. It is classified into three types based on tissue composition: Type I (purely cystic), Type II (mixed cystic and solid), and Type III (purely solid), with higher types carrying a worse prognosis. PPB is part of the DICER1 tumour predisposition syndrome, which also includes thyroid tumours, cystic nephroma, and other neoplasms.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Pleuropulmonary Blastoma trials.
DICER1 germline mutation testing is central to eligibility for DICER1 syndrome studies; pursue genetic counselling and documented mutation status early.
PPB type (I, II, or III) directly influences trial eligibility; confirm histopathological classification from a specialist paediatric pathology centre.
Many paediatric oncology trials require enrolment at or referral to an affiliated centre; contact the International PPB/DICER1 Registry for guidance on participating sites.
Patient Resources
Find recruiting Pleuropulmonary Blastoma trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Pleuropulmonary Blastoma. Updated daily.